|Traded as||SIX: LONN, SGX: O6Z|
|Richard Ridinger (CEO), Rolf Soiron (Chairman)|
|Products||Biopharmaceuticals, organic and fine chemicals, chemical synthesis equipment, custom manufacturing of chemicals and related products|
|Revenue||CHF 2.680 billion (2010)|
|CHF 374 million (2010)|
|Profit||CHF 291 million (2010)|
|Total assets||CHF 4.778 billion (end 2010)|
|Total equity||CHF 2.387 billion (end 2010)|
Number of employees
Lonza Group is a Swiss multinational, chemicals and biotechnology company, headquartered in Basel, with major facilities in the United States, United Kingdom, Spain, Brazil, Singapore, China, and the Czech Republic. The company provides product development services to the pharmaceutical and biologic industries, including organic, fine and performance chemicals, custom manufacturing of biopharmaceuticals, chemical synthesis capabilities, detection systems and services for the bioscience sector. Today, Lonza employs over 10,000 full time employees in over 30 countries.
Lonza was founded in 1897 in the small Swiss town of Gampel, situated in the canton of Valais, taking its name from the nearby river. Initially the company produced electricity used to manufacture chemicals such as calcium carbide. Lonza moved to neighbouring Visp (where it retains a production site today) in 1909 and began manufacturing synthetic fertilisers, and moves into vitamins, acids, intermediates and additives followed. In 1974, the group merged with aluminium firm Alusuisse, after which the group moved into the biotechnology sector. Lonza de-merged from the Alusuisse-Lonza Group in 1999 and listed on the SWX Swiss Exchange.
The company expanded in the United States in 1969 and acquired smaller biopharmaceutical units in recent years. In 1996, Lonza acquired Celltech Biologics and began producing mammalian cell cultures and monoclonal antibodies. In October 2011, Lonza acquired American firm Arch Chemicals for $1.4 billion, as a result becoming the world's largest manufacturer of biocides. On 15 August 2016, the group announced its intention to acquire InterHealth Nutraceuticals, a leader in research, development, manufacture and marketing of value-added nutritional ingredients for use in dietary supplements. The acquisition of the US based company will be done at a value of up to USD 300m. In December 2016, the company announced it would acquire Capsugel for $5.5 billion, from private equity firm KKR.
Lonza is involved in the manufacturing of biologics with several pharmaceutical companies. Lonza entered into a partnership with Teva in 2009 to develop and manufacture biosimilars. In 2010, they made a deal with GlaxoSmithKline to manufacture therapeutic monoclonal antibodies. In 2014, Lonza entered into an agreement with Bristol-Myers Squibb to manufacture two biologic drugs. Lonza also manufactures Imbruvica for Pharmacyclics and Mydicar for Celladon. In 2015, Lonza contracted with Alexion to construct a new facility dedicated to Alexion manufacturing. In 2017, Lonza and Sanofi partnered to construct a new facility for production of biologics. 
- "Annual Results 2010" (PDF). Lonza Group. Retrieved 5 February 2011.
- Lonza to invest Rs 250 cr in Genome Valley | Business Standard
- Allotment 30 Acres of Land in the “Genome Valley”
- Lonza Group to set up a bio pharma unit at Genome Valley
- Simonian, Haig (11 July 2011). "Lonza in $1.4bn acquisition of Arch Chemicals". Financial Times. Retrieved 13 November 2011.